


*B 1*

- (a) administering the compound to a patient;
- (b) monitoring a marker selected from the group consisting of tissue factor, CD40, u-PA, ETS-1, IL8, and t-PA;
- (c) constructing a standard curve; and
- (d) determining the efficacious dose based on the standard curve.

---

*B 2*

Claim 7. (Amended) The method of claim 5, wherein said compound is an indolinone compound, having the structure set forth in formula I:



wherein

- (a) R1, R2, R3, and R4 are selected from the group consisting of hydrogen, trihalomethyl, hydroxyl, amine, thioether, cyano, alkoxy, alkyl, amino, bromo, fluoro, chloro, iodo, mercapto, thio, cyandamido, alkylthio, aryl, heteroaryl, carboxyl, ester, oxo, alkoxy carbonyl, alkenyl, alkoxy, nitro, alkoxyl, and amido moieties; and
- (b) R5, is an optionally substituted aryl or heteroaryl cyclic moiety; or a pharmaceutically acceptable salt, ester, amide, prodrug, isomer, or metabolite thereof.